Your session is about to expire
← Back to Search
Fingolimod Hydrochloride for Breast Cancer
Study Summary
This trial is testing whether fingolimod can prevent nerve pain caused by chemotherapy in breast cancer patients. Fingolimod suppresses immune reactions in the brain, and this study will see if it can reduce neuropathy caused by paclitaxel.
- Breast Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any additional experiments that have been conducted using Fingolimod Hydrochloride?
"At present, 9 clinical trials are assessing Fingolimod Hydrochloride's efficacy. Out of these, 3 have reached Phase 3. Most studies concerning the drug are situated in Göttingen and Campania; however, 334 different medical sites across the world are trialing it."
Has this type of clinical experiment ever been conducted before?
"Since 2013, Novartis Pharmaceuticals has been invested in researching Fingolimod Hydrochloride; the initial trial involving 220 patients was concluded and Phase 3 approval granted. Currently, 9 trials of this drug are taking place across 135 cities worldwide, spanning 40 nations."
What is the overall count of participants in this experiment?
"At the present time, this medical experiment is not actively seeking participants. Although first posted on May 24th 2019 and last updated July 6th 2022, other clinical trials are available for those with breast cancer: 2287 studies in total, plus 9 investigations related to Fingolimod Hydrochloride."
Is enrollment currently open for this trial?
"Unfortunately, this clinical trial is not currently enrolling. Originally posted on May 24th 2019 and last updated July 6th 2022, it is no longer seeking out candidates. Those searching for other options have 2287 trials actively recruiting patients with breast cancer, as well as 9 studies involving Fingolimod Hydrochloride that are still taking in participants."
What therapeutic objectives is Fingolimod Hydrochloride commonly employed to achieve?
"Fingolimod Hydrochloride may be beneficial for treating carcinoma in situ, active secondary progressive multiple sclerosis (SPMS), and other forms of Multiple Sclerosis."
Has Fingolimod Hydrochloride been endorsed by the FDA?
"With limited efficacy and safety data, Fingolimod Hydrochloride scores a 1 on the assessment scale."
Share this study with friends
Copy Link
Messenger